Apeikon Therapeutics has developed novel Magnetic Resonance (MR) imaging and Focused Ultrasound (MRgFUS) targeted triggered treatments (3T technology) to address unmet clinical needs.
This novel platform technology involves the labelling of proprietary drug-filled carriers for MR imaging that can help to focus thousands of ultrasound transducers in a lesion within the body. This has the advantage of concentrating the drug dose in a tumour for optimum therapeutic effect while limiting the systemic toxicity.
This technology is suitable for use with both existing approved and experimental anticancer agents and it has the capacity to co-deliver drugs for combination therapy. In preclinical studies in cancer models, 3T platform technology has demonstrated greater efficacy compared with unencapsulated drugs.
3T technology patent applications have been filed in the EU and US.